ArticleArchives of medical science : AMS2025
Resumption versus discontinuation of direct oral anticoagulation after an episode of gastrointestinal bleeding: a systematic review and meta-analysis of rebleeding episodes.
Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- From empirical hemostasis to precision reversal: clinical challenges, technological innovations, and individualized strategies in anticoagulant-associated bleeding.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Direct oral anticoagulants (DOACs) have become standard of care in long-term anticoagulation. Extensive research has focused on this new class of drugs that, despite their benefits, have an associated risk of bleeding with lack of evidence for management following an episode of gastrointestinal bleeding (GIB). Our meta-analysis and systematic review provide an updated perspective on the rate of rebleeding in patients with an episode of GIB while on DOACs. Material and methods: A systematic search of PubMed, Embase and Cochrane databases was performed for all comparative studies examining outcomes in patients who resumed versus withheld DOACs after a baseline episode of GIB. The initial search found 1823 studies. After excluding duplicates and unrelated studies based on abstract triage, 29 full texts were assessed for eligibility, out of which five matched the inclusion criteria and were systematically reviewed. Results: Five studies containing data comparing clinical outcomes between patients were included. All studies were retrospective, including a total of 2837 patients, with a case control design. Both groups showed similar rebleeding rates with lower GIB as the primary site of rebleeding. Type of DOAC, timing of anticoagulation resumption and patient characteristics may influence rebleeding rates. Conclusions: Considering the overall risk/benefit ratio of anticoagulation after GIB, our findings suggest a potential benefit for oral anticoagulation continuation. Further large-scale studies are needed to provide optimal management strategies in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.